{"ticker": {"uuid": "0caa9df0-fa80-47bf-ae3e-157fdb86a9f4", "symbol": "2509", "name": "Qyuns Therapeutics Co., Ltd.", "exchange": "HKG", "country": "HK", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Price to book forward of Qyuns Therapeutics Co., Ltd. Class H \u2013 HKEX:2509", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOcVhUS0E2N0ZDT2tYMThDR1NfejlMMUdLNmpHSGRPSEFkUWVIYUEyZVJWektMV0ZFeXNMXzNkeTFIME9UeVlneFEwTDUwZ1dfTEJ3R01nWjdJeTJYOEo0UV9HV3llV09KcmhPT1Q5VndmekJwMXpvNDB0bWZTMmh2OU5iTWpZNlBLdnAxRkVKbDgtaUN3Ukw5Q1ln?oc=5", "source_name": "TradingView", "published_at": "2026-07-17T08:33:10+00:00", "published_display": "17 Jul 2026 08:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "China\u2019s Qyuns moves IL-17 biologic toward first approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQRmh2dmJyUlF1S1RpMGVQZFRRZ1BYWFBqM2FDUFVGNVRpSmRDN1BlbDBSTUFPTS1OS0YwRHV4LW42NTFvS0NwRDV0TjVpM2F0dlRPYXZjTG9HOXQ3d2p6eXZGcklmb2tkZ2NHTGRXeEFLcUdIRW1BZDNYZE90N0daUXhYMGNMME0yT2ZTOThzVDNtdUlIMExpdzgyTVo?oc=5", "source_name": "BioWorld News", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Qyuns and Roche partner in $1B+ bispecific antibody deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQOVdDamNUWE40U294N3poX3prS2F2cjVkTU1STEJnMks0UTZuSk9ZczF4bld0ZWhoYUdlWDdRNGxhUGZSd3M0T3R6X1otNjN5X0lJZXZUbmppSDBsRHVzQTROTjcxY2lQNFhJR19LVlVxYnhKd0ctY1BGYmM2VGtVcWx1M0NvTjdjemxIbnVLZlZSbnZCV0oxVXVINA?oc=5", "source_name": "BioWorld News", "published_at": "2025-10-29T07:00:00+00:00", "published_display": "29 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Price to book forward of Qyuns Therapeutics Co., Ltd. Class H \u2013 HKEX:2509", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOcVhUS0E2N0ZDT2tYMThDR1NfejlMMUdLNmpHSGRPSEFkUWVIYUEyZVJWektMV0ZFeXNMXzNkeTFIME9UeVlneFEwTDUwZ1dfTEJ3R01nWjdJeTJYOEo0UV9HV3llV09KcmhPT1Q5VndmekJwMXpvNDB0bWZTMmh2OU5iTWpZNlBLdnAxRkVKbDgtaUN3Ukw5Q1ln?oc=5", "source_name": "TradingView", "published_at": "2026-07-17T08:33:10+00:00", "published_display": "17 Jul 2026 08:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "China\u2019s Qyuns moves IL-17 biologic toward first approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQRmh2dmJyUlF1S1RpMGVQZFRRZ1BYWFBqM2FDUFVGNVRpSmRDN1BlbDBSTUFPTS1OS0YwRHV4LW42NTFvS0NwRDV0TjVpM2F0dlRPYXZjTG9HOXQ3d2p6eXZGcklmb2tkZ2NHTGRXeEFLcUdIRW1BZDNYZE90N0daUXhYMGNMME0yT2ZTOThzVDNtdUlIMExpdzgyTVo?oc=5", "source_name": "BioWorld News", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Qyuns and Roche partner in $1B+ bispecific antibody deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQOVdDamNUWE40U294N3poX3prS2F2cjVkTU1STEJnMks0UTZuSk9ZczF4bld0ZWhoYUdlWDdRNGxhUGZSd3M0T3R6X1otNjN5X0lJZXZUbmppSDBsRHVzQTROTjcxY2lQNFhJR19LVlVxYnhKd0ctY1BGYmM2VGtVcWx1M0NvTjdjemxIbnVLZlZSbnZCV0oxVXVINA?oc=5", "source_name": "BioWorld News", "published_at": "2025-10-29T07:00:00+00:00", "published_display": "29 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 76, "total_relevant": 3, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 3, "score": 50, "total": 3, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 54, "events": [{"event": "general", "label": "Market update", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 15.29, "latest_week": "2026-07-10", "one_week_move": -0.7, "four_week_move": -4.5, "twelve_week_move": -25.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.170048, "market_dynamics_buy_signal": false, "relative_strength": -21.272333, "fair_value_gap": -15.8, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 49.5127, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.7% over one week, -4.5% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 39, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "BioWorld News", "count": 2}, {"label": "TradingView", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 3}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 1}, {"label": "Regulatory and legal", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "54/100 classification confidence."}, {"label": "Company focus", "value": "3", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.7% over one week, -4.5% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Price to book forward of Qyuns Therapeutics Co., Ltd. Class H \u2013 HKEX:2509"}], "updated_at": "2026-07-18T01:16:26.741134+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}